-
Akari Therapeutics NASDAQ:AKTX Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.
Location: 24 W 40th St Fl 8, New York, 10018-1028, US | Website: akaritx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
63.11B
Cash
4.177M
Avg Qtr Burn
-3.949M
Short % of Float
-
Insider Ownership
37.61%
Institutional Own.
1.53%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nomacopan Details Paroxysmal nocturnal hemoglobinuria | Phase 3 Update | |
Nomacopan Details Hematopoietic stem cell transplantation thrombotic microangiopathies | Phase 3 Initiation | |
Nomacopan Details COVID-19 | Phase 2 Update | |
Nomacopan Details Atopic Keratoconjunctivitis | Phase 1/2 Update | |
Nomacopan Details Geographic atrophy, Eye disease | Phase 1 Initiation | |
Nomacopan Details Bullous pemphigoid | Failed Discontinued |